glp 1 insulin combo Practice Nursing - GLP-1 receptor agonists and their role in managing type 2 diabetes GLP-1 Agonists: A Comprehensive Overview

A 2023 study found a 20% cardiovascular risk reduction for obese individuals taking semaglutide compared to those not taking a GLP-1 drug

Since T3 directly stimulates hair follicle keratinocyte proliferation, even subtle declines can slow hair growth or push follicles into premature catagen and telogen

This innovative medication is designed to mimic the activity of two key hormones that regulate blood sugar levels and appetite, making it a valuable option for our patients

The semaglutide versus tirzepatide comparison helps weigh the options

VA users with type 2 diabetes (T2D) who used sulfonylureas or GLP-1RAs between 2017 and 2023 were identified, with follow-up extending until the outcome occurred, 3 years after treatment initiation, or 31 December 2024, whichever came first

The Journal of the American Medical Association recently published diet and exercise guidance for people taking GLP-1s (3): Source: Mehrtash F, Dushay J, Manson JE